Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The new anti-acne treatment HA-P5 effectively reduces acne by targeting two key receptors and avoids an enzyme that can hinder treatment.

Methotrexate is effective for treating rheumatoid arthritis but requires regular monitoring.

Ritlecitinib effectively treats severe Alopecia Areata by reducing harmful immune activity in the skin.

CD8+ T cells are involved in alopecia areata and may cause disease relapse.

JAK inhibitors are effective for treating alopecia areata, with most patients seeing hair growth after treatment.

Dupilumab improves eczema in Netherton Syndrome but not ichthyosis linearis circumflexa.

Most patients experienced mild to moderate skin problems during a trial for a desmoid tumor treatment.

Infliximab successfully treated a severe hair loss case in Sri Lanka.

Finasteride and dutasteride increase sexual dysfunction reports.

An 8-year-old girl with vitiligo developed extra hair growth on her knee after using tacrolimus ointment.

Laminin-511 is involved in psoriasis development and can be regulated by cannabinoid receptor type 1.

Topical immunotherapy is still effective for managing alopecia areata, even with new treatments available.

Upadacitinib may cause hair loss.

Microneedling with Triamcinolone acetonide is an effective, less invasive, and safe alternative to direct injections for treating alopecia areata.

Etretinate was effective for certain skin conditions, but caused side effects like chapped lips, dry mucous membranes, and hair loss.

Interest in JAK inhibitors for hair loss increased significantly after media coverage and FDA approval.

Infections during JAK inhibitor treatment for alopecia areata are usually manageable and rarely stop treatment permanently.

Baricitinib is effective for treating severe alopecia areata in Japanese patients, but long-term safety needs more study.

Recombinant Human Annexin A5 may help treat localized scleroderma by reducing skin thickening and inflammation.

Janus kinase inhibitors may help treat cutaneous T-cell lymphoma, but more research is needed.

The document concludes that various topical treatments show promise for skin conditions like atopic dermatitis, psoriasis, and hair loss.

Tocilizumab therapy may cause skin and hair conditions like halo naevi, vitiligo, and alopecia areata.

A man developed temporary hair loss after taking a cancer drug, which might indicate a better treatment response.

JAK inhibitors, like ruxolitinib, may effectively treat frontal fibrosing alopecia.

Skin side effects from melanoma immunotherapy are common and may indicate better survival.

Deucravacitinib did not significantly improve hair regrowth in alopecia areata patients.

Guselkumab significantly improves psoriasis symptoms within 12 weeks.

Dupilumab may cause significant hair loss, which can reverse after stopping the drug.